主页 > 医学前沿 >
【文摘发布】马拉威地区氯喹对疟疾重新有效
Author: Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV.
Resourse: N Engl J Med. 2006 Nov 9;355(19):1959-66.
BACKGROUND: In 1993, Malawi became the first country in Africa to replace chloroquine with the combination of sulfadoxine and pyrimethamine for the treatment of malaria. At that time, the clinical efficacy of chloroquine was less than 50%. The molecular marker of chloroquine-resistant falciparum malaria subsequently declined in prevalence and was undetectable by 2001, suggesting that chloroquine might once again be effective in Malawi. METHODS: We conducted a randomized clinical trial involving 210 children with uncomplicated Plasmodium falciparum malaria in Blantyre, Malawi. The children were treated with either chloroquine or sulfadoxine\#8211;pyrimethamine and followed for 28 days to assess the antimalarial efficacy of the drug. RESULTS: In analyses conducted according to the study protocol, treatment failure occurred in 1 of 80 participants assigned to chloroquine, as compared with 71 of 87 participants assigned to sulfadoxine\#8211;pyrimethamine. The cumulative efficacy of chloroquine was 99% (95% confidence interval [CI], 93 to 100), and the efficacy of sulfadoxine\#8211;pyrimethamine was 21% (95% CI, 13 to 30). Among children treated with chloroquine, the mean time to parasite clearance was 2.6 days (95% CI, 2.5 to 2.8) and the mean time to the resolution of fever was 10.3 hours (95% CI, 8.1 to 12.6). No unexpected adverse events related to the study drugs occurred. CONCLUSIONS: Chloroquine is again an efficacious treatment for malaria, 12 years after it was withdrawn from use in Malawi. (ClinicalTrials.gov number, NCT00125489 [ClinicalTrials.gov].).
PMID: 17093247 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Title: Return of chloroquine antimalarial efficacy in Malawi.
标题：马拉威地区氯喹对疟疾重新有效
Author: Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV.
作者：Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV.
Resourse: N Engl J Med. 2006 Nov 9;355(19):1959-66.
文章来源：新英格兰医学杂志.2006.11.9; 355(19):1959-66.
BACKGROUND: In 1993, Malawi became the first country in Africa to replace chloroquine with the combination of sulfadoxine and pyrimethamine for the treatment of malaria. At that time, the clinical efficacy of chloroquine was less than 50%.
背景：
在1993年，马拉威成为非洲第一个用磺胺邻二甲氧嘧啶联合乙胺嘧啶代替氯喹治疗疟疾的国家。那时氯喹的临床治疗效果小于50%。
The molecular marker of chloroquine-resistant falciparum malaria subsequently declined in prevalence and was undetectable by 2001, suggesting that chloroquine might once again be effective in Malawi.
对氯喹有抗药性的恶性疟的分子特点在随后的流行中衰落下来，到2001年几乎消失，这说明在马拉威氯喹可以重新有效。
METHODS: We conducted a randomized clinical trial involving 210 children with uncomplicated Plasmodium falciparum malaria in Blantyre, Malawi.
方法：
我们进行了一项随机临床试验，纳入马拉威Blantyre 的210名非重症恶性疟儿童患者。
The children were treated with either chloroquine or sulfadoxine\#8211;pyrimethamine and followed for 28 days to assess the antimalarial efficacy of the drug.
这些儿童接受氯喹治疗，或者接受磺胺邻二甲氧嘧啶联合乙胺嘧啶治疗，28天后，评价这些药物的抗疟效果。
RESULTS: In analyses conducted according to the study protocol, treatment failure occurred in 1 of 80 participants assigned to chloroquine, as compared with 71 of 87 participants assigned to sulfadoxine\#8211;pyrimethamine.
结果：
根据研究记录所进行的分析显示，氯喹组的治疗失败率为1/80，磺胺邻二甲氧嘧啶联合乙胺嘧啶组为71 / 87。
The cumulative efficacy of chloroquine was 99% (95% confidence interval [CI], 93 to 100), and the efficacy of sulfadoxine\#8211;pyrimethamine was 21% (95% CI, 13 to 30).
氯喹的累积药效为99%（(95%置信区间，分布：93－100)，而磺胺邻二甲氧嘧啶联合乙胺嘧啶为21% (95% CI, 13 － 30)。
Among children treated with chloroquine, the mean time to parasite clearance was 2.6 days (95% CI, 2.5 to 2.8) and the mean time to the resolution of fever was 10.3 hours (95% CI, 8.1 to 12.6).
用氯喹治疗的儿童，其寄生虫平均清除时间为2.6天(95% CI, 2.5 to 2.8)，平均退烧时间为10.3小时(95% CI, 8.1 to 12.6)。
No unexpected adverse events related to the study drugs occurred. CONCLUSIONS: Chloroquine is again an efficacious treatment for malaria, 12 years after it was withdrawn from use in Malawi. (ClinicalTrials.gov number, NCT00125489 [ClinicalTrials.gov].).
没有与研究药物相关的意外不良事件发生。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-11-12 05:11
医学,生命科学网